Second CAR t dose shows promise for tough lymphoma

NCT ID NCT05794958

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This study is testing whether a second dose of a CAR T-cell therapy called Axi-Cel is safe for people with a type of blood cancer called large B-cell lymphoma that is hard to treat. About 20 adults who have already had standard CAR T treatment but are at high risk of their cancer coming back will receive a second infusion. The main goal is to check for side effects, and researchers will also track how long patients stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    RECRUITING

    Palo Alto, California, 94305, United States

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.